Keywords
Last Name
Institution

Jim C. Oates

TitleDirector, Division of Rheumatology
InstitutionMedical University of South Carolina
DepartmentMedicine
AddressP.O. Box MSC 637
Suite 822
Clinical Science Bldg. - 96 Jonathan Lucas St.
Phone843-792-3484
Fax843-792-7121
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Jim Oates is a professor and Associate Director in the Division of Rheumatology and Immunology at the Medical University of South Carolina. He received a BS in chemistry at Bates College and a medical degree from Johns Hopkins School of Medicine in 1991. He completed his internship and residency in internal medicine and fellowship in rheumatology at Duke University Medical Center in 1996. He came to the Medical University of South Carolina in 1996 to complete a research fellowship and joined the faculty of the Division of Rheumatology in 1997. He became Chief of the Rheumatology Service at the Ralph H Johnson VA Medical Center in 2007, the Informatics Medical Director of Research and Reporting in 2013, and Vice Chair for Research in the Department of Medicine in 2016.

    Dr. Oates' clinical and research interests are focused on systemic lupus erythematosus. He is involved in clinical trials of therapies for systemic lupus erythematosus and lupus nephritis and is the principal investigator on several studies at MUSC involving noninvasive markers of disease and mechanisms through which disease severity may increase among African-Americans. Dr. Oates is an active member of the M.U.S.C.L.E. Research Group. His translational work is focused on the role of reactive intermediates and oxidative stress in the endothelial dysfunction that leads to atherosclerosis and renal disease in patients with lupus. He is also studying machine learning biomarker models of outcome in lupus nephritis.

    He has supported clinical research at a regional and national level by serving as the President American Federation for Medical Research and the President of the Southern Society for Clinical Investigation, where he also serves as an Associate Editor of its journal, the American Journal of Medical Sciences.

    He has received numerous awards, including Phi Beta Kappa from Bates College, the Four Schools Physician Scientist Training Program Scholarship from the Johns Hopkins School of Medicine, the Senior Rheumatology Scholar Award from the American College of Rheumatology (ACR), the Arthritis Investigator Award from the ACR and its foundation, the Research Education Foundation (REF), the Merck Young Investigator Award, the REF/European League Against Rheumatism International Exchange Award, and the Developing Scholar Award from the Medical University of South Carolina Health Sciences Foundation.

    Collapse keywords
    Healthy Volunteer Studies, Autoimmune disease, Lupus

    Collapse ORNG Applications 
    Collapse Featured Videos
    Collapse studies/trials

    Collapse Research 
    Collapse research activities and funding
    R01AR045476     (OATES, JAMES C)Apr 23, 1999 - May 31, 2013
    NIH
    Role of reactive intermediates in lupus nephritis
    Role: Principal Investigator

    K08AR002193     (OATES, JAMES C)Apr 25, 2001 - Feb 28, 2006
    NIH
    Role of nitric oxide and eicosanoids in lupus nepthritis
    Role: Principal Investigator

    R21AR051719     (OATES, JAMES C)Sep 20, 2004 - Jun 30, 2007
    NIH
    Urine protein markers of disease in lupus nephritis
    Role: Principal Investigator

    I01CX000218     (OATES, JAMES C)Apr 1, 2010 - Mar 31, 2014
    NIH
    Urine biomarkers of lupus nephritis pathology and response to therapy
    Role: Principal Investigator

    P60AR062755     (GILKESON, GARY S)Jul 1, 2012 - Jun 30, 2017
    NIH
    MCRC for Rheumatic Diseases in African Americans
    Role: Co-Investigator

    I01CX001248     (OATES, JAMES C)Jul 1, 2016 - Jun 30, 2019
    NIH
    Targeting Pathogenic Endothelial Dysfunction in Systemic Lupus Erythematosus
    Role: Principal Investigator

    P30AR072582     (GILKESON, GARY S)Sep 25, 2017 - Aug 31, 2022
    NIH
    Improving Minority Health in Rheumatic Diseases
    Role: Co-Investigator

    R01AR071947     (TSAO, BETTY P.)May 27, 2018 - Apr 30, 2023
    NIH
    Predictive Biomarkers for disease activity and organ damage in patients with lupus
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Faith TD, Flournoy-Floyd M, Ortiz K, Egede LE, Oates JC, Williams EM. My life with lupus: contextual responses of African-American women with systemic lupus participating in a peer mentoring intervention to improve disease self-management. BMJ Open. 2018 Nov 08; 8(11):e022701. PMID: 30413505.
      View in: PubMed
    2. Shoaibi A, Obeid JS, Oates JC, Habrat ML, Lenert LA. The association between method of solicitation and patient permissions for use of surplus tissues and contact for future research. JAMIA Open. 2018 Oct; 1(2):195-201. PMID: 30474075.
      View in: PubMed
    3. Putterman C, Pisetsky DS, Petri M, Caricchio R, Wu AHB, Sanz I, Oates JC, Wallace S, Sorek R, Gerwien R, Safer P, Jakobi-Brook K, Cohen IR. The SLE-key test serological signature: new insights into the course of lupus. Rheumatology (Oxford). 2018 09 01; 57(9):1632-1640. PMID: 29873771.
      View in: PubMed
    4. Obeid JS, Shoaibi A, Oates JC, Habrat ML, Hughes-Halbert C, Lenert LA. Research participation preferences as expressed through a patient portal: implications of demographic characteristics. JAMIA Open. 2018 Oct; 1(2):202-209. PMID: 30474076.
      View in: PubMed
    5. Williams EM, Hyer JM, Viswanathan R, Faith TD, Voronca D, Gebregzaibher M, Oates JC, Egede L. Peer-to-Peer Mentoring for African American Women With Lupus: A Feasibility Pilot. Arthritis Care Res (Hoboken). 2017 Nov 21. PMID: 29161471.
      View in: PubMed
    6. Turner CA, Jacobs AD, Marques CK, Oates JC, Kamen DL, Anderson PE, Obeid JS. Word2Vec inversion and traditional text classifiers for phenotyping lupus. BMC Med Inform Decis Mak. 2017 Aug 22; 17(1):126. PMID: 28830409.
      View in: PubMed
    7. Buie JJ, Renaud LL, Muise-Helmericks R, Oates JC. IFN-a Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus. J Immunol. 2017 09 15; 199(6):1979-1988. PMID: 28779021.
      View in: PubMed
    8. Ruiz D, Oates JC, Kamen DL. Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus. Am J Med Sci. 2018 Mar; 355(3):293-298. PMID: 29549933.
      View in: PubMed
    9. Williams EM, Hyer JM, Viswanathan R, Faith TD, Egede L, Oates JC, Marshall GD. Cytokine balance and behavioral intervention; findings from the Peer Approaches to Lupus Self-Management (PALS) project. Hum Immunol. 2017 Sep; 78(9):574-581. PMID: 28716698.
      View in: PubMed
    10. Flournoy-Floyd M, Ortiz K, Egede L, Oates JC, Faith TD, Williams EM. "We Would Still Find Things to Talk About": Assessment of Mentor Perspectives in a Systemic Lupus Erythematosus Intervention to Improve Disease Self-Management, Empowering SLE Patients. J Natl Med Assoc. 2018 Apr; 110(2):182-189. PMID: 29580453.
      View in: PubMed
    11. Marshall EA, Oates JC, Shoaibi A, Obeid JS, Habrat ML, Warren RW, Brady KT, Lenert LA. A population-based approach for implementing change from opt-out to opt-in research permissions. PLoS One. 2017; 12(4):e0168223. PMID: 28441388.
      View in: PubMed
    12. Williams EM, Egede L, Faith T, Oates J. Effective Self-Management Interventions for Patients With Lupus: Potential Impact of Peer Mentoring. Am J Med Sci. 2017 06; 353(6):580-592. PMID: 28641721.
      View in: PubMed
    13. Yazdany J, Bansback N, Clowse M, Collier D, Law K, Liao KP, Michaud K, Morgan EM, Oates JC, Orozco C, Reimold A, Simard JF, Myslinski R, Kazi S. Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement. Arthritis Care Res (Hoboken). 2016 Dec; 68(12):1866-1873. PMID: 27696755.
      View in: PubMed
    14. Williams EM, Bruner L, Adkins A, Vrana C, Logan A, Kamen D, Oates JC. I too, am America: a review of research on systemic lupus erythematosus in African-Americans. Lupus Sci Med. 2016; 3(1):e000144. PMID: 27651918.
      View in: PubMed
    15. Williams EM, Lorig K, Glover S, Kamen D, Back S, Merchant A, Zhang J, Oates JC. Intervention to Improve Quality of life for African-AmericaN lupus patients (IQAN): study protocol for a randomized controlled trial of a unique a la carte intervention approach to self-management of lupus in African Americans. BMC Health Serv Res. 2016 08 02; 16(a):339. PMID: 27485509.
      View in: PubMed
    16. Wolf BJ, Spainhour JC, Arthur JM, Janech MG, Petri M, Oates JC. Development of Biomarker Models to Predict Outcomes in Lupus Nephritis. Arthritis Rheumatol. 2016 08; 68(8):1955-63. PMID: 26867033.
      View in: PubMed
    17. Oates JC. Presentation of the 2016 Founders' Medal Award. Am J Med Sci. 2016 07; 352(1):6-8. PMID: 27432030.
      View in: PubMed
    18. Barnado A, Crofford LJ, Oates JC. At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. J Leukoc Biol. 2016 Feb; 99(2):265-78. PMID: 26658004.
      View in: PubMed
    19. Putterman C, Wu A, Reiner-Benaim A, Batty DS, Sanz I, Oates J, Jakobi K, Petri M, Safer P, Gerwien R, Sorek R, Blumenstein Y, Cohen IR. SLE-key(®) rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP(®). J Immunol Methods. 2016 Feb; 429:1-6. PMID: 26678162; PMCID: PMC4824168 [Available on 02/01/17].
    20. Kamen DL, Oates JC. A Pilot Study to Determine if Vitamin D Repletion Improves Endothelial Function in Lupus Patients. Am J Med Sci. 2015 Oct; 350(4):302-7. PMID: 26351776.
      View in: PubMed
    21. Mashmoushi AK, Oates JC. Lipopolysaccharide induces inducible nitric oxide synthase-dependent podocyte dysfunction via a hypoxia-inducible factor 1a and cell division control protein 42 and Ras-related C3 botulinum toxin substrate 1 pathway. Free Radic Biol Med. 2015 Jul; 84:185-195. PMID: 25765888; PMCID: PMC4457627.
    22. Oates JC. Endothelial dysfunction in injury and inflammation. Am J Med Sci. 2015 Jan; 349(1):2. PMID: 25535885.
      View in: PubMed
    23. Sato S, Lennard Richard M, Brandon D, Jones Buie JN, Oates JC, Gilkeson GS, Zhang XK. A critical role of the transcription factor fli-1 in murine lupus development by regulation of interleukin-6 expression. Arthritis Rheumatol. 2014 Dec; 66(12):3436-44. PMID: 25155007; PMCID: PMC4245454.
    24. Williams EM, Bruner L, Penfield M, Kamen D, Oates JC. Stress and Depression in Relation to Functional Health Behaviors in African American Patients with Systemic Lupus Erythematosus. Rheumatology (Sunnyvale). 2014; 2014(Suppl 4). PMID: 26618072.
      View in: PubMed
    25. Nowling TK, Mather AR, Thiyagarajan T, Hernández-Corbacho MJ, Powers TW, Jones EE, Snider AJ, Oates JC, Drake RR, Siskind LJ. Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis. J Am Soc Nephrol. 2015 Jun; 26(6):1402-13. PMID: 25270066; PMCID: PMC4446878.
    26. Afrin LB, Oates JC, Kamen DL. Improving clinical trial accrual by streamlining the referral process. Int J Med Inform. 2015 Jan; 84(1):15-23. PMID: 25256066.
      View in: PubMed
    27. Jones Buie JN, Oates JC. Role of interferon alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase-related mechanisms. Am J Med Sci. 2014 Aug; 348(2):168-75. PMID: 24796291; PMCID: PMC4526236.
    28. Williams EM, Zhang J, Zhou J, Kamen D, Oates JC. Predictors of non-response and non-compliance in African American lupus patients: Findings from the Balancing Lupus Experiences with Stress Strategies (BLESS) Study. Int J Med Biomed Sci. 2014 Feb; 2(1):6-19. PMID: 25664344.
      View in: PubMed
    29. Williams EM, Penfield M, Kamen D, Oates JC. An Intervention to Reduce Psychosocial and Biological Indicators of Stress in African American Lupus Patients: The Balancing Lupus Experiences with Stress Strategies Study. Open J Prev Med. 2014 Jan; 4(1):22-31. PMID: 24999444.
      View in: PubMed
    30. Williams EM, Kamen D, Penfield M, Oates JC. Stress Intervention and Disease in African American Lupus Patients: The Balancing Lupus Experiences with Stress Strategies (BLESS) Study. Health (Irvine Calif). 2014 Jan; 6(1):71-79. PMID: 24932382.
      View in: PubMed
    31. Oates JC, Mashmoushi AK, Shaftman SR, Gilkeson GS. NADPH oxidase and nitric oxide synthase-dependent superoxide production is increased in proliferative lupus nephritis. Lupus. 2013 Nov; 22(13):1361-70. PMID: 24106214; PMCID: PMC3839955.
    32. Reese C, Dyer S, Perry B, Bonner M, Oates J, Hofbauer A, Sessa W, Bernatchez P, Visconti RP, Zhang J, Hatfield CM, Silver RM, Hoffman S, Tourkina E. Differential regulation of cell functions by CSD peptide subdomains. Respir Res. 2013 Sep 08; 14:90. PMID: 24011378.
      View in: PubMed
    33. Gilkeson GS, Mashmoushi AK, Ruiz P, Caza TN, Perl A, Oates JC. Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis. PLoS One. 2013; 8(5):e64650. PMID: 23741359; PMCID: PMC3669382.
    34. Ramos PS, Oates JC, Kamen DL, Williams AH, Gaffney PM, Kelly JA, Kaufman KM, Kimberly RP, Niewold TB, Jacob CO, Tsao BP, Alarcón GS, Brown EE, Edberg JC, Petri MA, Ramsey-Goldman R, Reveille JD, Vilá LM, James JA, Guthridge JM, Merrill JT, Boackle SA, Freedman BI, Scofield RH, Stevens AM, Vyse TJ, Criswell LA, Moser KL, Alarcón-Riquelme ME, Langefeld CD, Harley JB, Gilkeson GS. Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry. J Rheumatol. 2013 Jun; 40(6):842-9. PMID: 23637325.
      View in: PubMed
    35. Oates JC. The magic of the Southern Society for Clinical Investigation: can we make the vanishing physician-scientist reappear? Am J Med Sci. 2013 Apr; 345(4):259. PMID: 23531953.
      View in: PubMed
    36. Snider AJ, Ruiz P, Obeid LM, Oates JC. Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis. PLoS One. 2013; 8(1):e53521. PMID: 23301082; PMCID: PMC3536755.
    37. Ravenell RL, Kamen DL, Spence JD, Hollis BW, Fleury TJ, Janech MG, Almeida JS, Shaftman SR, Oates JC. Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. Am J Med Sci. 2012 Oct; 344(4):268-73. PMID: 22222338; PMCID: PMC3323721.
    38. Al Gadban MM, German J, Truman JP, Soodavar F, Riemer EC, Twal WO, Smith KJ, Heller D, Hofbauer AF, Oates JC, Hammad SM. Lack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupus. Cell Immunol. 2012 Mar-Apr; 276(1-2):42-51. PMID: 22560558; PMCID: PMC3399025.
    39. Taylor TP, Janech MG, Slate EH, Lewis EC, Arthur JM, Oates JC. Overcoming the effects of matrix interference in the measurement of urine protein analytes. Biomark Insights. 2012; 7:1-8. PMID: 22403482; PMCID: PMC3290108.
    40. Tourkina E, Bonner M, Oates J, Hofbauer A, Richard M, Znoyko S, Visconti RP, Zhang J, Hatfield CM, Silver RM, Hoffman S. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair. 2011 Jul 01; 4(1):15. PMID: 21722364.
      View in: PubMed
    41. Oates JC, Halushka PV, Hutchison FN, Ruiz P, Gilkeson GS. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis. Am J Med Sci. 2011 Feb; 341(2):101-5. PMID: 20924284; PMCID: PMC3022955.
    42. Tourkina E, Richard M, Oates J, Hofbauer A, Bonner M, Gööz P, Visconti R, Zhang J, Znoyko S, Hatfield CM, Silver RM, Hoffman S. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis. 2010 Jun; 69(6):1220-6. PMID: 20410070.
      View in: PubMed
    43. Oates JC. The biology of reactive intermediates in systemic lupus erythematosus. Autoimmunity. 2010 Feb; 43(1):56-63. PMID: 20001422; PMCID: PMC2857664.
    44. Qin Z, Freitas E, Sullivan R, Mohan S, Bacelieri R, Branch D, Romano M, Kearney P, Oates J, Plaisance K, Renne R, Kaleeba J, Parsons C. Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress. PLoS Pathog. 2010 Jan 29; 6(1):e1000742. PMID: 20126446; PMCID: PMC2813276.
    45. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan; 62(1):222-33. PMID: 20039413; PMCID: PMC4548300.
    46. Scofield RH, Oates J. The place of William Osler in the description of systemic lupus erythematosus. Am J Med Sci. 2009 Nov; 338(5):409-12. PMID: 19826244; PMCID: PMC2783313.
    47. Andrews N, Burris JE, Cech TR, Coller BS, Crowley WF, Gallin EK, Kelner KL, Kirch DG, Leshner AI, Morris CD, Nguyen FT, Oates J, Sung NS. Translational careers. Science. 2009 May 15; 324(5929):855. PMID: 19443750; PMCID: PMC2869292.
    48. Njoku C, Self SE, Ruiz P, Hofbauer AF, Gilkeson GS, Oates JC. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene. J Investig Med. 2008 Oct; 56(7):911-9. PMID: 18797415; PMCID: PMC2637653.
    49. Oates JC, Shaftman SR, Self SE, Gilkeson GS. Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis Rheum. 2008 Jan; 58(1):263-72. PMID: 18163495; PMCID: PMC2733831.
    50. Oates JC, Farrelly LW, Hofbauer AF, Wang W, Gilkeson GS. Association of reactive oxygen and nitrogen intermediate and complement levels with apoptosis of peripheral blood mononuclear cells in lupus patients. Arthritis Rheum. 2007 Nov; 56(11):3738-47. PMID: 17968874; PMCID: PMC2733836.
    51. Bouali H, Nietert P, Nowling TM, Pandey J, Dooley MA, Cooper G, Harley J, Kamen DL, Oates J, Gilkeson G. Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus. J Rheumatol. 2007 Oct; 34(10):2028-34. PMID: 17896805; PMCID: PMC2798120.
    52. Yu L, Wang J, O'Dell JR, Oates J, Arend WP, Eisenbarth GS. Anti-dsDNA antibody assay: high specificity and sensitivity with a filtration radioassay in comparison to low specificity with the standard ELISA. J Rheumatol. 2007 Apr; 34(4):734-9. PMID: 17407230.
      View in: PubMed
    53. Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS, Arthur JM. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol. 2007 Mar; 18(3):913-22. PMID: 17301191; PMCID: PMC2733832.
    54. Oates J. Renal biopsy at the onset of clinical lupus nephritis: can it yield useful information? J Rheumatol. 2007 Feb; 34(2):256-8. PMID: 17304650; PMCID: PMC2700631.
    55. Oates JC, Gilkeson GS. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clin Immunol. 2006 Dec; 121(3):243-50. PMID: 16861040; PMCID: PMC2765327.
    56. Oates JC, Varghese S, Bland AM, Taylor TP, Self SE, Stanislaus R, Almeida JS, Arthur JM. Prediction of urinary protein markers in lupus nephritis. Kidney Int. 2005 Dec; 68(6):2588-92. PMID: 16316334; PMCID: PMC2667626.
    57. Njoku CJ, Patrick KS, Ruiz P, Oates JC. Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis. J Investig Med. 2005 Nov; 53(7):347-52. PMID: 16297360.
      View in: PubMed
    58. Donovan JL, DeVane CL, Chavin KD, Oates JC, Njoku C, Patrick KS, Fiorini RN, Markowitz JS. Oral administration of a decaffeinated green tea (Camellia sinensis) extract did not alter urinary 8-epi-prostaglandin F(2 alpha), a biomarker for in-vivo lipid peroxidation. J Pharm Pharmacol. 2005 Oct; 57(10):1365-9. PMID: 16259767.
      View in: PubMed
    59. Bogatkevich GS, Gustilo E, Oates JC, Feghali-Bostwick C, Harley RA, Silver RM, Ludwicka-Bradley A. Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol. 2005 Jan; 288(1):L190-201. PMID: 15447940.
      View in: PubMed
    60. Tourkina E, Gooz P, Oates JC, Ludwicka-Bradley A, Silver RM, Hoffman S. Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am J Respir Cell Mol Biol. 2004 Jul; 31(1):28-35. PMID: 14742295.
      View in: PubMed
    61. Oates JC, Gilkeson GS. Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice. J Investig Med. 2004 Jan; 52(1):62-71. PMID: 14989372.
      View in: PubMed
    62. Afrin LB, Oates JC, Boyd CK, Daniels MS. Leveraging of open EMR architecture for clinical trial accrual. AMIA Annu Symp Proc. 2003; 16-20. PMID: 14728125.
      View in: PubMed
    63. Oates JC, Levesque MC, Hobbs MR, Smith EG, Molano ID, Page GP, Hill BS, Weinberg JB, Cooper GS, Gilkeson GS. Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in african-americans. J Rheumatol. 2003 Jan; 30(1):60-7. PMID: 12508391.
      View in: PubMed
    64. Oates JC, Gilkeson GS. Mediators of injury in lupus nephritis. Curr Opin Rheumatol. 2002 Sep; 14(5):498-503. PMID: 12192244.
      View in: PubMed
    65. Oates JC, Reilly CM, Crosby MB, Gilkeson GS. Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases. Arthritis Rheum. 2002 Mar; 46(3):598-605. PMID: 11920394.
      View in: PubMed
    66. Reilly CM, Oates JC, Sudian J, Crosby MB, Halushka PV, Gilkeson GS. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin Immunol. 2001 Mar; 98(3):337-45. PMID: 11237557.
      View in: PubMed
    67. Crofford LJ, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F, Morrow JD, McDonagh KT, Schmaier AH. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum. 2000 Aug; 43(8):1891-6. PMID: 10943882.
      View in: PubMed
    68. Reilly CM, Oates JC, Cook JA, Morrow JD, Halushka PV, Gilkeson GS. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol. 2000 Feb 01; 164(3):1498-504. PMID: 10640767.
      View in: PubMed
    69. Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. Proc Assoc Am Physicians. 1999 Nov-Dec; 111(6):611-21. PMID: 10591091.
      View in: PubMed
    70. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol. 1999 Feb; 26(2):318-24. PMID: 9972965.
      View in: PubMed
    71. Oates JC, Ruiz P, Alexander A, Pippen AM, Gilkeson GS. Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol. 1997 Apr; 83(1):86-92. PMID: 9073540; PMCID: PMC4570564.
    72. Woosley RL, Roden DM, Dai GH, Wang T, Altenbern D, Oates J, Wilkinson GR. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther. 1986 Mar; 39(3):282-7. PMID: 3081292.
      View in: PubMed
    Oates's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _